Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (OLE)
NCT07747506Phase 2Not yet recruiting
- Sponsor
- Verastem Oncology
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib, defactinib in Low grade serous ovarian cancer (LGSOC), sponsored by Verastem Oncology. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT07747506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07747506.